BCTXL · BriaCell Therapeutics Corp. · Debt
$0.93
+0.03 (+3.33%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Jun 9, 2026
Substantial doubt about the company's ability to continue as a going concern.
“However, the Company's ability to continue as a going concern is dependent upon its ability to attain future profitable operations and to continue to obtain the necessary financing to meet its obligations arising from normal business operations when they come due. The uncertainty of the Company's ability to raise such financial capital casts substantial doubt on the Company's ability to continue as a going concern.”View the 10-Q filed Jun 9, 2026
Market Cap
$31.17M
Shares
8.70M
Volume · Oct 21
17.14K
Avg daily vol (43 sessions)
16.28K
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current unsecured bank loans received, including current portion of noncurrent unsecured bank loans | 2020-07-31 | CAD 306,878 | 40-F/A filed 2021-11-16 |
| Current unsecured bank loans received, including current portion of noncurrent unsecured bank loans | 2020-07-31 | USD 249,799 | 40-F/A filed 2021-11-16 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.